Clinical Trial: A clinical study on the efficacy and safety of the novel CDK2/4/6 inhibitor cummeciclib in the treatment of patients with advanced HR+/HER2- breast cancer (China)

Posted On: 2026-08-11

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A clinical study on the efficacy and safety of the novel CDK2/4/6 inhibitor cummeciclib in the treatment of patients with advanced HR+/HER2- breast cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129581

Registration Time: 2026/08/06

Type: Interventional study

Primary Sponsor: The affiliated people's hospital of Ningbo University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336795

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A clinical study on the efficacy and safety of the novel CDK2/4/6 inhibitor cummeciclib in the treatment of patients with advanced HR+/HER2- breast cancer (China)